Neurofilament Light Chain Determination from Peripheral Blood Samples

2015 ◽  
pp. 93-98 ◽  
Author(s):  
Marguerite Limberg ◽  
Giulio Disanto ◽  
Christian Barro ◽  
Jens Kuhle
Keyword(s):  
Light Chain ◽  
Peripheral Blood ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Blood Samples

scholarly journals Peripheral blood neurofilament light chain levels: the neurologist’s C-reactive protein?

Brain ◽  
2018 ◽  
Vol 141 (8) ◽  
pp. 2235-2237 ◽  
Author(s):  
Gavin Giovannoni
Keyword(s):  
Light Chain ◽  
Peripheral Blood ◽  
C Reactive Protein ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Reactive Protein

scholarly journals Comparison of neurofilament light chain results between two independent facilities

2020 ◽  
Vol 2 (2) ◽  
pp. e000063
Author(s):  
Tobias Sejbaek ◽  
Jason P Mendoza ◽  
Natasha Penner ◽  
Jonna Skov Madsen ◽  
Dorte Aalund Olsen ◽  
...  
Keyword(s):  
Light Chain ◽  
Plasma Concentrations ◽  
Plasma Samples ◽  
Normal Range ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Blood Samples ◽  
Laboratory Facilities ◽  
Highly Correlated ◽  
Sensitivity Specificity

ObjectivesTo examine levels of neurofilament light chain (NFL) in identical cerebrospinal fluid (CSF) and blood samples at two different facilities, and how differences affect interpretation of levels within and above the normal range.MethodsCSF and plasma from patients with multiple sclerosis (MS) and healthy controls (HCs) were analysed by Simoa (Quanterix) for levels of NFL providing a total of 165 CSF samples (119 from MS) and 225 plasma samples (180 from MS).ResultsCSF and plasma concentrations highly correlated between NFL laboratory facilities (R: 0.92 and 0.84, <0.0001, respectively), and there were no differences between facilities. A bias between the two sites for plasma was −0.95 pg/mL and for CSF −73.53 pg/mL. The cut-offs for CSF were 807.5 and 571.0 pg/mL at site 1 and site 2, respectively; the cut-offs for plasma were 13.0 and 11.8 pg/mL, respectively. Seven out of 180 plasma samples (3.9%) and 3 out of 119 CSF samples (2.5%) from MS patients could be reclassified as normal/abnormal, that is, below/above cut-off, when measured at different facilities.ConclusionOur study demonstrates that results of NFL in CSF and blood measured with SIMOA are comparable between facilities. Nevertheless, healthcare practitioners should consider reference values at different laboratories, since different sensitivity/specificity can affect interpretation when low values are adjacent to cut-offs.

scholarly journals Elevated Levels of Serum Neurofilament Light Chain Associated with Cognitive Impairment in Vascular Dementia

2020 ◽  
Vol 2020 ◽  
pp. 1-5
Author(s):  
Weibin Ma ◽  
Jingjing Zhang ◽  
Jialei Xu ◽  
Depeng Feng ◽  
Xiaoling Wang ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Decline ◽  
Vascular Dementia ◽  
Single Molecule ◽  
Light Chain ◽  
Peripheral Blood ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Biochemical Characteristics ◽  
Significant Difference

Objective. Vascular dementia (VaD) is a progressive neurodegenerative disease with cognitive decline caused by cerebrovascular factors. Despite the great progress made in the past decade, VaD still lacks effective treatments and peripheral blood biomarkers. In this study, we tested the level of peripheral blood neurofilament light chain (NfL) in VaD patients and explored its relationship with cognitive impairment. Method. A total of 176 study subjects including 80 normal controls (NC) and 96 VaD patients were included in our study. Upon admission, we collected clinical and biochemical characteristics of all research subjects. We also evaluate the Montreal cognitive assessment scale (MoCA) scores of all subjects. The serum NfL level was measured by the single-molecule array (Simoa) method. Results. The years of education in the NC group and VaD group were ( 11.65 ± 3.04 ) years and ( 10.53 ± 3.87 ) years, respectively. Compared with VaD patients, the NC group has a higher level of education ( p = 0.037 ). Furthermore, the results of Simoa indicated that VaD subjects had higher serum NfL levels compared with the NC group [( 8.49 ± 2.37 ) pg/ml vs. ( 19.26 ± 4.71 ) pg/ml, p < 0.001 ]. In terms of other clinical and biochemical characteristics, there was no significant difference between VaD and NC. The Spearman correlation analysis indicated that educational years have a significant positive correlation with MoCA scores ( r = 0.238 , p = 0.041 ), while age and serum NfL levels have a significantly negative correlation with MoCA scores (age: r = − 0.213 , p = 0.040 ; NfL: r = − 0.395 , p = 0.027 ). However, further multiple regression analysis showed that only serum NfL level might serve as an independent risk factor for cognitive decline in VaD ( β = 0.317 , p = 0.021 ). Conclusion. The serum NfL levels in VaD subjects are significantly elevated, which may be used as a potential peripheral blood marker for predicting cognitive impairment in patients with VaD.

Blast exposure results in tau and neurofilament light chain changes in peripheral blood

Brain Injury ◽  
2020 ◽  
Vol 34 (9) ◽  
pp. 1213-1221
Author(s):  
Katie A. Edwards ◽  
Jacqueline J. Leete ◽  
Anna E. Tschiffely ◽  
Candace Y. Moore ◽  
Kristine C. Dell ◽  
...  
Keyword(s):  
Light Chain ◽  
Peripheral Blood ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Blast Exposure

Biological Variation of Serum Neurofilament Light Chain in Healthy Subjects

2020 ◽  
Author(s):  
Claus Vinter Bødker Hviid ◽  
Anne Tranberg Madsen ◽  
Anne Winther-Larsen
Keyword(s):  
Light Chain ◽  
Healthy Subjects ◽  
Biological Variation ◽  
Neurofilament Light Chain ◽  
Neurofilament Light

Increased frequency of proinflammatory CD4 T cells and pathological levels of serum neurofilament light chain in adult drug‐resistant epilepsy

Epilepsia ◽  
2020 ◽  
Author(s):  
Oumarou Ouédraogo ◽  
Rose‐Marie Rébillard ◽  
Hélène Jamann ◽  
Victoria Hannah Mamane ◽  
Marie‐Laure Clénet ◽  
...  
Keyword(s):  
T Cells ◽  
Light Chain ◽  
Cd4 T Cells ◽  
Drug Resistant ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Drug Resistant Epilepsy

scholarly journals Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications

2021 ◽  
pp. jnnp-2021-326914
Author(s):  
Dario Saracino ◽  
Karim Dorgham ◽  
Agnès Camuzat ◽  
Daisy Rinaldi ◽  
Armelle Rametti-Lacroux ◽  
...  
Keyword(s):  
Single Molecule ◽  
Light Chain ◽  
Rate Of Change ◽  
Longitudinal Change ◽  
Youden Index ◽  
Clinical Genetic ◽  
Neurofilament Light Chain ◽  
Neurofilament Light ◽  
Link Type ◽  
Therapeutic Trials

ObjectiveNeurofilament light chain (NfL) is a promising biomarker in genetic frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). We evaluated plasma neurofilament light chain (pNfL) levels in controls, and their longitudinal trajectories in C9orf72 and GRN cohorts from presymptomatic to clinical stages.MethodsWe analysed pNfL using Single Molecule Array (SiMoA) in 668 samples (352 baseline and 316 follow-up) of C9orf72 and GRN patients, presymptomatic carriers (PS) and controls aged between 21 and 83. They were longitudinally evaluated over a period of >2 years, during which four PS became prodromal/symptomatic. Associations between pNfL and clinical–genetic variables, and longitudinal NfL changes, were investigated using generalised and linear mixed-effects models. Optimal cut-offs were determined using the Youden Index.ResultspNfL levels increased with age in controls, from ~5 to~18 pg/mL (p<0.0001), progressing over time (mean annualised rate of change (ARC): +3.9%/year, p<0.0001). Patients displayed higher levels and greater longitudinal progression (ARC: +26.7%, p<0.0001), with gene-specific trajectories. GRN patients had higher levels than C9orf72 (86.21 vs 39.49 pg/mL, p=0.014), and greater progression rates (ARC:+29.3% vs +24.7%; p=0.016). In C9orf72 patients, levels were associated with the phenotype (ALS: 71.76 pg/mL, FTD: 37.16, psychiatric: 15.3; p=0.003) and remarkably lower in slowly progressive patients (24.11, ARC: +2.5%; p=0.05). Mean ARC was +3.2% in PS and +7.3% in prodromal carriers. We proposed gene-specific cut-offs differentiating patients from controls by decades.ConclusionsThis study highlights the importance of gene-specific and age-specific references for clinical and therapeutic trials in genetic FTD/ALS. It supports the usefulness of repeating pNfL measurements and considering ARC as a prognostic marker of disease progression.Trial registration numbersNCT02590276 and NCT04014673.

Sign in / Sign up

Export Citation Format

Share Document